Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BridgeBio Pharma (BBIO) Current Assets (2019 - 2025)

Historic Current Assets for BridgeBio Pharma (BBIO) over the last 7 years, with Q3 2025 value amounting to $839.4 million.

  • BridgeBio Pharma's Current Assets rose 8880.42% to $839.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $839.4 million, marking a year-over-year increase of 8880.42%. This contributed to the annual value of $720.7 million for FY2024, which is 5090.09% up from last year.
  • BridgeBio Pharma's Current Assets amounted to $839.4 million in Q3 2025, which was up 8880.42% from $912.3 million recorded in Q2 2025.
  • Over the past 5 years, BridgeBio Pharma's Current Assets peaked at $945.1 million during Q1 2021, and registered a low of $432.9 million during Q2 2023.
  • Over the past 5 years, BridgeBio Pharma's median Current Assets value was $695.2 million (recorded in 2025), while the average stood at $690.8 million.
  • Per our database at Business Quant, BridgeBio Pharma's Current Assets plummeted by 4387.46% in 2023 and then skyrocketed by 8880.42% in 2025.
  • Quarter analysis of 5 years shows BridgeBio Pharma's Current Assets stood at $888.9 million in 2021, then plummeted by 38.25% to $548.9 million in 2022, then fell by 12.98% to $477.6 million in 2023, then skyrocketed by 50.9% to $720.7 million in 2024, then grew by 16.47% to $839.4 million in 2025.
  • Its Current Assets stands at $839.4 million for Q3 2025, versus $912.3 million for Q2 2025 and $695.2 million for Q1 2025.